Immunocore Holdings plc (IMCR)
Develops immune-based cancer and infectious disease treatments using engineered T cells.
$33.43-0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+1.3%
The outlook
IMCR is trading near its 50- and 200-day averages with analyst consensus leaning Buy. The stock sits roughly midway in its 52-week range, and the average analyst price target is about 90% above the current price, reflecting significant gap between current valuation and analyst expectations.
What’s behind the score
Analyst consensusBuy — 1.7 avg of 11 analysts
Price trendAbove its 50- & 200-day averages
52-week range45% of the way from its 52-week low to high
Price targetAvg target +90% vs current price
Analyst price target
~12-month · 11 analysts$63.49average target+90.0% vs now
Now $33.43
Low $34.00High $100.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.70B
52-wk high
$40.72
52-wk low
$27.56
50-day avg
$30.75
200-day avg
$32.50
Trailing P/E
—